This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Alternative options for women taking continuous combined oral HRT preparation containing 1mg of oestradiol

Authoring team

Alternative options for women taking continuous combined oral HRT preparation containing 1mg of oestradiol

Women taking continuous combined oral HRT preparation containing 1mg of oestradiol, can consider the following:

  • Bijuve capsule 1mg oestradiol + 100 mg progesterone

  • Femoston conti 1mg oestradiol + 5mg dydrogesterone

  • Kliovance 1mg oestradiol + 0.5mg norethisterone acetate

  • Indivina 1mg oestradiol + 2.5mg medroxyprogesterone acetate

  • Indivina 1mg oestradiol + 5mg medroxyprogesterone acetate

  • Or take oestrogen and progestogen separately:
    • Oral oestradiol 1mg plus either:
      • micronised progesterone: Utrogestan 100 mg orally at night daily on continuous basis
      • Or Provera 5mg orally daily on continuous basis
      • Or Norethisterone 5mg orally daily on continuous basis (1mg would be sufficient for use in a continuous combined regimen but not available in stand-alone preparations)
        • Off license use of norethisterone in progestogen only contraceptive pills (e.g. Noriday 3 x tablets of 350 micrograms a day, will provide 1.05 mg of norethisterone) may be considered as an equivalent alternative
      • Or Mirena IUS

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.